A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Hepatitis B Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02604212
• Other study ID #: Heparc-2003
• Secondary ID: 2014-004751-31
• Status: Terminated
• Phase: Phase 2
• Start date: November 2015
• Est. completion date: December 2016

Study information

• Verified date: January 2019
• Source: Arrowhead Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with HBeAG positive, chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.

Description:

This is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study of ARC-520 in combination with entecavir or tenofovir administered to patients with HBeAg positive and immune active chronic HBV infection Eligible patients who have signed an Ethics Committee - approved informed consent, will be enrolled and will receive ARC-520 or placebo in combination with entecavir or tenofovir. The study will enroll up to a total of 90 eligible chronic HBV infected patients. Patients will undergo the following evaluations at regular intervals during the study: medical history, physical examinations, vital sign measurements (blood pressure, heart rate, respiratory rate and temperature), weight, adverse events assessment (AEs), 12 lead electrocardiograms (ECGs), liver fibrosis testing, concomitant medication assessment, blood sample collection for hematology, coagulation, chemistry, lactate, Pharmacokinetic (PK) measures (in a subset of patients), exploratory Pharmacodynamic (PD) measures, urinalysis, HBV serology, Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing for females of childbearing potential. Clinically significant changes including AEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the patient is lost to follow-up. For each patient the duration of the study is approximately 33 weeks from screening to the Day 169 follow-up visit. For patients enrolling into a planned extension study, the total duration of this study is approximately 25 weeks from screening to Day 113 end of study visit.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 32
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Male or female, 18 to 75 years of age.

• Written informed consent.

• No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment.

• No new abnormal finding of clinical relevance at the screening evaluation.

• Diagnosis of HBeAg positive, immune active, chronic HBV infection.

• > 2months of continuous treatment with daily, oral entecavir or tenofovir.

• Willingness to continue taking entecavir or tenofovir throughout the study.

• Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive) (both male and female partners).

Exclusion Criteria:

• Pregnant or lactating

• Acute signs of hepatitis/other infection within 4 weeks of screening.

• Antiviral therapy other than entecavir or tenofovir within 3 months of screening.

• Prior treatment with interferon in the last 3 years.

• Use within the last 6 months or anticipated requirement for anticoagulants, corticosteroids, immunomodulators, or immunosuppressants.

• Use of prescription medication within 14 days prior to treatment administration except: topical products without systemic absorption, statins (except rosuvastatin), hypertension medications, or hormonal contraceptives.

• Depot injection or implant of any drug within 3 months prior to treatment administration, except injectable/implantable birth control.

• Diagnosis of diabetes mellitus.

• History of autoimmune disease especially autoimmune hepatitis.

• Human immunodeficiency virus (HIV) infection.

• Sero-positive for Hepatitis C Virus (HCV), and/or a history of delta virus hepatitis.

• Hypertension defined as blood pressure > 150/100 mmHg.

• History of cardiac rhythm disturbances.

• Family history or congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death.

• Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease within 6 months prior to study entry.

• History of malignancy except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer.

• Has had a major surgery within 3 months of screening.

• History of alcohol and/or drug abuse < 12 months from screening.

• Regular uses of alcohol within 6 months prior to screening (ie, more than 14 units of alcohol per week).

• Evidence of severe systemic acute inflammation, sepsis, or hemolysis.

• Diagnosed with a significant psychiatric disorder.

• Use of recreational drugs, such as marijuana, within 3 months prior to screening.

• Use of drugs such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year prior to screening.

• History of allergy to bee sting.

• Use of investigational agents or devices within 30 days prior to planned study dosing or current participation in an investigational study.

• Clinically significant history or presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease.

• Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction.

• Clinically significant history or presence of poorly controlled/uncontrolled systemic disease.

• History of fever within 2 weeks of screening.

• Immunized with a live attenuated vaccine within 7 days prior to dosing or planned vaccination (excluding flu vaccine by injection).

• Presence of any medical or psychiatric condition or social situation that impacts compliance or results in additional safety risk.

• Participated in excessive exercise/physical activity within 7 days of screening or planned during the trial.

• History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant medication(s).

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• ARC-520

Other:
• Placebo

Drug:
• entecavir
All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
• antihistamine
All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
• tenofovir
All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Locations

Country	Name	City	State
China	Prince of Wales Hospital	Hong Kong
China	Queen Mary Hospital	Hong Kong
Germany	Klinikum der Johann Wolfgang Goethe Universitaet	Frankfurt
Germany	Asklepios Klinik St. Georg - Chirurgisch-Traumatologisches Zentrum	Hamburg
Germany	Medizinische Hochschule Hannover	Hannover
Germany	Eugastro Gmbh	Leipzig
Germany	Universitaetsklinikum Leipzig	Leipzig
Germany	Klinikum Der Ludwig-Maximilian-Universitaet Muenchen	Muenchen
Germany	University Hospital of Tuebingen	Tuebingen
Germany	Universitaetsklinikum Ulm, Klinik fur Innere Medizin I	Ulm
Germany	Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II	Wuerzburg
Korea, Republic of	Pusan National University Hospital	Busan
Korea, Republic of	Gachon University Gil Medical Center	Incheon
Korea, Republic of	Seoul National University Hospital	Seoul
Korea, Republic of	Severance Hospital, Yonsei University College of Medicine	Seoul
Korea, Republic of	Pusan National University Yangsan Hospital	Yangsan-si Gyeongnam

Sponsors (1)

Lead Sponsor	Collaborator
Arrowhead Pharmaceuticals

Countries where clinical trial is conducted

China,  Germany,  Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113	Change From Baseline in log qHBsAg at Day 113 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.	Baseline, Day 113
Secondary	Change From Baseline in Log qHBsAg Over Time	Change From Baseline in log qHBsAg up to Day 99 in response to multiple doses of ARC-520 versus placebo, using a a mixed effect model for repeated measures (MMRM). Includes parameter baseline as a continuous covariate, and treatment and visit as fixed factors, interaction of treatment and visit, and interaction of parameter baseline and visit.	Baseline, Days 15, 29, 43, 57, 71, 85, 99
Secondary	Change From Baseline at Day 15 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 15
Secondary	Change From Baseline at Day 29 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 29
Secondary	Change From Baseline at Day 43 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 43
Secondary	Change From Baseline at Day 57 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 57
Secondary	Change From Baseline at Day 71 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 71
Secondary	Change From Baseline at Day 85 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 85
Secondary	Change From Baseline at Day 99 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 99
Secondary	Change From Baseline at Day 113 in Log qHBsAg, by Category	Change in log qHBsAg from baseline, categorized into the following groups: no decrease, decrease > 0 to < 0.5 log IU/mL; decrease 0.5 to 1.0 log IU/mL; decrease > 1.0 log IU/mL, tabulated by dose and treatment for each visit.	Baseline, Day 113
Secondary	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs	An AE is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. A treatment emergent AE (TEAE) was defined as an AE that was not present prior to the first study drug administration and started at/after the time of initiation of administration of study drug, or an AE which was present prior to initiation of study drug administration, which increased in severity after study drug administration. An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.	Through Day 169 (± 3 days)
Secondary	Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Maximum Observed Plasma Concentration (Cmax)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Clearance (CL)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Apparent Volume of Distribution (V)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Terminal Elimination Rate Constant (Kel)		Through 48 hours post-dosing on Day 1 and Day 85
Secondary	Pharmacokinetics of ARC-520: Terminal Elimination Half-Life (t1/2)		Through 48 hours post-dosing on Day 1 and Day 85